scholarly journals A high-throughput amplicon screen for somatic UBA1 variants in Cytopenic and Giant Cell Arteritis cohorts

Author(s):  
James A. Poulter ◽  
Alesia Khan ◽  
Stephen Martin ◽  
Mark Grey ◽  
Bosko Andjelic ◽  
...  

AbstractSomatic mutations in the gene encoding the major E1 ubiquitin ligase, UBA1, were recently identified as a cause of VEXAS, a late-onset acquired auto-inflammatory syndrome. Differential diagnoses for patients subsequently found to have VEXAS include relapsing polychondritis, Sweet’s syndrome, myelodysplastic syndrome (MDS), giant cell arteritis (GCA) and undifferentiated systemic autoinflammatory disease (uSAID). We therefore sought to screen DNA from individuals with a non-diagnostic cytopenia or GCA, for known VEXAS-associated mutations. To this end, we developed a multiplexed UBA1 amplicon sequencing assay, allowing quick screening of large cohorts while also providing sufficient sequencing depth to identify somatic mutations to an allele frequency <1%. Using this assay, we screened genomic DNA from 612 males diagnosed with GCA, and bone marrow DNA from 1,055 cases with an undiagnosed cytopenia. No GCA cases were found to have UBA1 mutations, however 4 different mutations in the cytopenic cohort were identified in 7 individuals. Furthermore, we describe a female case identified in the screen with a UBA1 mutation and all VEXAS-associated phenotypes, but without Monosomy X. Our study suggests that, despite the overlap in clinical features, VEXAS is rarely misdiagnosed as GCA, but identified in 1.0% of males with an undiagnosed cytopenia. The identification of a UBA1 variant in a female case adds further evidence that VEXAS should not be ruled out as a differential diagnosis in females with VEXAS-like symptoms.Key points-Mutations in UBA1 exon 3 have been associated with VEXAS syndrome-UBA1 exon 3 was screened in 1650 patients with cytopenia or GCA by amplicon sequencing.-6 males were identified from the non-diagnostic cytopenia cohort (1.0%) with UBA1 mutations.-A female with a somatic UBA1 mutation was identified without Monosomy X

2021 ◽  
pp. jrheum.210149
Author(s):  
Carolyn Ross ◽  
Hannah Laure Elfassy ◽  
Jean-Paul Makhzoum

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome was recently discovered in 25 men with late-onset severe and refractory inflammatory syndromes and associated hematologic abnormalities. Various diseases have been described, such as relapsing polychondritis, myelodysplastic syndrome, polyarteritis nodosa, and giant cell arteritis.


2021 ◽  
Author(s):  
Thea G. Fennell ◽  
Grace A. Blackwell ◽  
Nicholas R. Thomson ◽  
Matthew J. Dorman

AbstractMembers of the bacterial genus Vibrio utilise chitin both as a metabolic substrate and a signal to activate natural competence. Vibrio cholerae is a bacterial enteric pathogen, sub-lineages of which can cause pandemic cholera. However, the chitin metabolic pathway in V. cholerae has been dissected using only a limited number of laboratory strains of this species. Here, we survey the complement of key chitin metabolism genes amongst 195 diverse V. cholerae. We show that the gene encoding GbpA, known to be an important colonisation and virulence factor in pandemic isolates, is not ubiquitous amongst V. cholerae. We also identify a putatively novel chitinase, and present experimental evidence in support of its functionality. Our data indicate that the chitin metabolic pathway within the V. cholerae species is more complex than previously thought, and emphasise the importance of considering genes and functions in the context of a species in its entirety, rather than simply relying on traditional reference strains.Impact statementIt is thought that the ability to metabolise chitin is ubiquitous amongst Vibrio spp., and that this enables these species to survive in aqueous and estuarine environmental contexts. Although chitin metabolism pathways have been detailed in several members of this genus, little is known about how these processes vary within a single Vibrio species. Here, we present the distribution of genes encoding key chitinase and chitin-binding proteins across diverse Vibrio cholerae, and show that our canonical understanding of this pathway in this species is challenged when isolates from non-pandemic V. cholerae lineages are considered alongside those linked to pandemics. Furthermore, we show that genes previously thought to be species core genes are not in fact ubiquitous, and we identify novel components of the chitin metabolic cascade in this species, and present functional validation for these observations.Data summaryThe authors confirm that all supporting data, code, and protocols have been provided within the article or through supplementary data files.No whole-genome sequencing data were generated in this study. Accession numbers for the publicly-available sequences used for these analyses are listed in Supplementary Table 1, Table 2, and the Methods.All other data which underpin the figures in this manuscript, including pangenome data matrices, modified and unmodified sequence alignments and phylogenetic trees, original images of gels and immunoblots, raw fluorescence data, amplicon sequencing reads, and the R code used to generate Figure 7, are available in Figshare: https://dx.doi.org/10.6084/m9.figshare.13169189(Note for peer-review: Figshare DOI is inactive but will be activated upon publication, please use temporary URL https://figshare.com/s/7795a2d80c13f694f8fa for review).


2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 873.2-874
Author(s):  
D. Semenov ◽  
K. LI ◽  
M. Turk ◽  
J. Pope

Background:Giant cell arteritis (GCA) is an immune-mediated disease of the large vessels, and occurs in adults over 50 years old1. It is the most commonly seen form of chronic vasculitis and is associated with significant rates of morbidity2. This meta-analysis examines the geographical and temporal epidemiology of GCA, including incidence, prevalence and mortality.Objectives:To identify changes in incidence rate, prevalence, and mortality rate over timeTo compare these rates between geographic regions around the worldMethods:A systematic review of the English literature was conducted using the EMBase, Scopus and PubMed databases. Articles were included if they were cohort or cross-sectional studies with 50 or more patients with GCA and reported on population, location and time-frame parameters. Articles on mortality were included if they compared mortality to age and gender matched population. Review articles, case-control studies and case series were excluded. Two reviewers extracted data and a third verified inclusion of studies. Study quality was assessed by using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist. Mortality rate was standardized across cohorts to deaths per 1000 people per year.Results:Of the 3569 citations identified by the literature search, 107 were included in analysis. The pooled incidence of GCA internationally was 10.00 [9.22, 10.78] cases per 100 000 people over 50 years old (Figure). This incidence was highest in Scandinavia 21.57 [18.90, 24.23], followed by North and South America 10.89 [8.78, 13.00], Europe 7.26 [6.05, 8.47], and Oceania 7.85 [1.48,17.19]. Nine studies reported prevalence. Pooled prevalence from these 9 was 51.74 [42.04,61.43] cases per 100 000 people over 50 years old. Overall, pooled mortality was 20.44 [17.84,23.03] deaths/1000 per year. Mortality had a generally decreasing trend over the years of publication.Conclusion:The incidence of GCA varies regionally almost 3-fold. Likely genetic and environmental factors may explain this trend. Incidence and prevalence are important for tracking the efficacy and side effects of current therapies, as well as planning for the costs of biologic treatment.References:[1] Floris A, Piga M, Cauli A, Salvarani C, Mathieu A. Polymyalgia rheumatica: an autoinflammatory disorder?. RMD Open. 2018;4(1):e000694. Published 2018 Jun 4. doi:10.1136/rmdopen-2018-000694[2] Crow RW, Katz BJ, Warner JE, et al. Giant cell arteritis and mortality. J Gerontol A Biol Sci Med Sci. 2009;64(3):365–369. doi:10.1093/gero na/gln030Acknowledgments:Both Daniel Semenov and Katherine Li equally contributed and sharing first authorshipFunding in part was from the Canadian Rheumatology Association summer studentshipDisclosure of Interests:Daniel Semenov: None declared, Katherine Li: None declared, Matthew Turk: None declared, Janet Pope Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, Merck, Roche, Seattle Genetics, UCB, Consultant of: AbbVie, Actelion, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eicos Sciences, Eli Lilly & Company, Emerald, Gilead Sciences, Inc., Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Speakers bureau: UCB


2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 230.2-230 ◽  
Author(s):  
M.A.C. Alba ◽  
A. García-Martínez ◽  
G. Espigol-Frigole ◽  
I. Tavera-Bahillo ◽  
S. Prieto-González ◽  
...  

VASA ◽  
2015 ◽  
Vol 44 (3) ◽  
pp. 0229-0232 ◽  
Author(s):  
Francesco Sciotto ◽  
Jörg D. Seebach ◽  
Johannes A. Lobrinus ◽  
Hala Kannuna ◽  
David Carballo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document